Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.
Evaluation of the Role of Sonoclot Signature in Assessment of Coagulopathy in Critically Ill COVID 19 Patients
1 other identifier
observational
70
1 country
1
Brief Summary
Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2020
CompletedStudy Start
First participant enrolled
July 20, 2020
CompletedFirst Posted
Study publicly available on registry
July 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 16, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
August 16, 2020
CompletedSeptember 9, 2020
September 1, 2020
27 days
July 19, 2020
September 7, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
clot rate formation
measuring how rapid the sample will get clotted
30 minutes
Study Arms (2)
Covid19 positive patients
Covid19 negative patients
Interventions
studying coagulation disorders in COVID19 critically ill patients
Eligibility Criteria
patients who are suspected to be COVID 19 infection
You may qualify if:
- COVID 19 critically ill patients
You may not qualify if:
- any critical illness not related to COVID 19
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut university
Asyut, 71111, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of clinical pathology
Study Record Dates
First Submitted
July 19, 2020
First Posted
July 21, 2020
Study Start
July 20, 2020
Primary Completion
August 16, 2020
Study Completion
August 16, 2020
Last Updated
September 9, 2020
Record last verified: 2020-09